Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models

Zhou, Runhong1,2; Wang, Pui2,3; Wong, Yik-Chun1,2; Xu, Haoran1,2; Lau, Siu-Ying2,3; Liu, Li1,2,3; Mok, Bobo Wing-Yee2,3,4; Peng, Qiaoli1,2,6,7; Liu, Na1,2; Woo, Kin-Fai1,2; Deng, Shaofeng2,3; Tam, Rachel Chun-Yee2,3; Huang, Haode1,2; Zhang, Anna Jinxia2,3,4; Zhou, Dongyan1,2,4; Zhou, Biao1,2; Chan, Chun-Yin1,2; Du, Zhenglong1,2; Yang, Dawei1,2; Au, Ka-Kit1,2; Yuen, Kwok-Yung2,3,4,5; Chen, Honglin2,3,4,5; Chen, Zhiwei1,2,3,4,5

2022

10.1016/j.ebiom.2021.103762

EBioMedicine   影响因子和分区

2352-3964

["Background Vaccines in emergency use are efficacious against COVID-19, yet vaccine-induced prevention against nasal SARS-CoV-2 infection remains suboptimal.","Methods Since mucosal immunity is critical for nasal prevention, we investigated the efficacy of an intramuscular PD1-based receptor-binding domain (RBD) DNA vaccine (PD1-RBD-DNA) and intranasal live attenuated influenzabased vaccines (LAIV-CA4-RBD and LAIV-HK68-RBD) against SARS-CoV-2.","Findings Substantially higher systemic and mucosal immune responses, including bronchoalveolar lavage IgA/IgG and lung polyfunctional memory CD8 T cells, were induced by the heterologous PD1-RBD-DNA/LAIV-HK68-RBD as compared with other regimens. When vaccinated animals were challenged at the memory phase, prevention of robust SARS-CoV-2 infection in nasal turbinate was achieved primarily by the heterologous regimen besides consistent protection in lungs. The regimen-induced antibodies cross-neutralized variants of concerns. Furthermore, LAIV-CA4-RBD could boost the BioNTech vaccine for improved mucosal immunity.","Interpretation Our results demonstrated that intranasal influenza-based boost vaccination induces mucosal and systemic immunity for effective SARS-CoV-2 prevention in both upper and lower respiratory systems. Copyright (C) 2021 The Author(s). Published by Elsevier B.V."]

SARS-CoV-2 Receptor binding domain Mucosal immunity Nasal prevention PD1-based DNA vaccine Live-attenuated influenza-based vaccine

SCI

英语

其他

General & Internal Medicine ; Research & Experimental Medicine

Medicine, General & Internal ; Medicine, Research & Experimental

WOS:000795167400010

ELSEVIER

Web of Science

1.Univ Hong Kong, Li Ka Shing Fac Med, AIDS Inst, Pokfulam, Hong Kong, Peoples R China
2.Univ Hong Kong, Li Ka Shing Fac Med, Dept Microbiol, Pokfulam, L5-45,21 Sassoon Rd, Hong Kong, Peoples R China
3.Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China
4.Univ Hong Kong, Ctr Virol Vaccinol & Therapeut Ltd, Hong Kong, Peoples R China
5.Univ Hong Kong, Dept Clin Microbiol & Infect Control, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China
6.Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, Peoples Hosp Shenzhen 3, Shenzhen, Guangdong, Peoples R China
7.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China

Zhou, Runhong,Wang, Pui,Wong, Yik-Chun,et al. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models[J]. EBioMedicine,2022,75.

Zhou, Runhong.,Wang, Pui.,Wong, Yik-Chun.,Xu, Haoran.,Lau, Siu-Ying.,...&Chen, Zhiwei.(2022).Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.EBioMedicine,75.

Zhou, Runhong,et al."Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models".EBioMedicine 75(2022).